Gynecologic cancer screening in the transgender male population and its current challenges.

As the transgender community gains visibility and recognition, healthcare disparities have become more apparent. Reports estimate that 1-1.5 million people belong to this community in the United States.

Treating urogenital atrophy.

Urogenital atrophy, although a frequently occurring symptom of aging for all women, is a condition often not thought of as a symptom of distress for older women or a sign of pelvic pathology requiring treatment by clinicians. Rather, many clinicians feel it is an expected consequence of aging, and older women themselves assimilate their lifestyle to the uncomfortable symptoms of dryness, irritation, itching and malodorous discharge. At times, when symptoms become intolerable with coitus, women will abandon sexual intercourse with their partners due to dyspareunia and not seek intervention to reverse the condition owing to embarrassment in raising this sensitive topic.

Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.

Background: Oophorectomy reduces serum testosterone levels. We studied the efficacy and safety of transdermal testosterone in treating hypoactive sexual desire disorder in surgically menopausal women.

Methods: A 24-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial was conducted in women (aged 24-70 years) who developed distressful low sexual desire after bilateral salpingo-oophorectomy and hysterectomy and who were receiving oral estrogen therapy.